BioLineRx Ltd. (BLRX) income statement
BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.15+0.03 (+2.68%)
Close on Nov 18, 2026Market cap $5.00MP/E –Yield –
BioLineRx Ltd. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- 80.5%
- Operating margin
- -871.8%
- Net margin
- –
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 1.20
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 33.8%
Valuation
- P/E ratio
- –
- Price to sales
- 4.24
- Price to book
- 0.36
- Dividend yield
- –
See a number that looks wrong?